Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 31 of the 33 references it cites were found in a registry or an index.

Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial

Abstract

Background Multiple sclerosis is associated with muscle stiffness, spasms, pain, and tremor. Much anecdotal evidence suggests that cannabinoids could help these symptoms. Our aim was to test the notion that cannabinoids have a beneficial effect on spasticity and other symptoms related to multiple sclerosis. Methods We did a randomised, placebo-controlled trial, to which we enrolled 667 patients with stable multiple sclerosis and muscle spasticity. 630 participants were treated at 33 UK centres with oral cannabis extract (n=211), Delta9-tetrahydrocannabinol (Delta9-THC; n=206), or placebo (n=213). Trial duration was 15 weeks. Our primary outcome measure was change in overall spasticity scores, using the Ashworth scale. Analysis was by intention to treat. Findings 611 of 630 patients were followed up for the primary endpoint. We noted no treatment effect of cannabinoids on the primary outcome (p=0.40). The estimated difference in mean reduction in total Ashworth score for participants taking cannabis extract compared with placebo was 0.32 (95% CI -1.04 to 1.67), and for those taking Delta9-THC versus placebo it was 0.94 (-0.44 to 2.31). There was evidence of a treatment effect on patient-reported spasticity and pain (p=0.003), with improvement in spasticity reported in 61% (n=121, 95% CI 54.6-68.2), 60% (n=108, 52.5-66.8), and 46% (n=91, 39.0-52.9) of participants on cannabis extract, Delta9-THC, and placebo, respectively. Interpretation Treatment with cannabinoids did not have…

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(03)14738-1

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 33 references

Research works printed but not linked: 6

  1. 1994, A double-blind, placebocontrolled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis, Neurology, 44, S70
  2. Smith, 1994, Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial, Neurology, 44, S34
  3. Riazi, 2003, Developing a patient-based measure of the impact of spasticity in multiple sclerosis, Multiple Sclerosis ECTRIMS, 9, S151
  4. Rog, 2003, Randomised controlled trial of cannabis-based medicinal extracts in the treatment of neuropathic pain due to multiple sclerosis, Multiple Sclerosis ECTRIMS, 9, S25
  5. Shakespeare, 2003, Anti-spasticity agents for multiple sclerosis (Cochrane Review)
  6. Wiffen, 2003, Anticonvulsant drugs for acute and chronic pain (Cochrane Review)

Cited by

See all 848

Metadata

Authors
Zajicek, J., Fox, P., Sanders, H., Wright, D., Vickery, J., Nunn, A., & Thompson, A.
Affiliations
  • Peninsula College of Medicine and Dentistry (GB)
  • University of Plymouth (GB)
  • MRC Clinical Trials Unit at UCL (GB)
  • University College Hospital (GB)
Corresponding author
Zajicek, John
Venue
The Lancet
Publisher
Elsevier BV
Published
2003-11
Volume
362
Issue
9395
Pages
1517-1526
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2140180096
Cited by
827
References
33
Citations by year
2026: 15 · 2025: 28 · 2024: 16 · 2023: 18 · 2022: 31 · 2021: 31 · 2020: 33 · 2019: 30 · 2018: 42 · 2017: 26 · 2016: 25 · 2015: 31 · 2014: 34 · 2013: 33 · 2012: 48
FWCI
37.30
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion)
  • ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
Funders
  • Multiple Sclerosis Society
  • Medical Research Council
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
  • Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
  • Health Sciences › Medicine › Clinical Neurology › Botulinum Toxin and Related Neurological Disorders
Keywords
multiple sclerosis, spasticity, cannabinoids, delta-9-tetrahydrocannabinol, Ashworth scale, pain, tremor, muscle stiffness, treatment effects
MeSH terms
Cannabidiol, Cannabinoids, Female, United Kingdom, Humans, Locomotion, Male, Middle Aged, Multiple Sclerosis, Muscle Spasticity, Physical Examination, Placebos, Dronabinol, Walking, Treatment Outcome, Outcome Assessment, Health Care, Secondary Prevention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. https://app.cochat.ai/papers/10.1016/s0140-6736(03)14738-1
The paper
Zajicek, J., Fox, P., Sanders, H., Wright, D., Vickery, J., Nunn, A., & Thompson, A. (2003). Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(03)14738-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.